Regulatory approval

Published by the Health Service Executive. Approved

Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pembrolizumab - ODMS; Pemetrexed, Cisplatin - N/A

Citation

Pembrolizumab, PEMEtrexed and CISplatin Therapy, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6890/569_V5_Pembrolizumab_PEMEtrexed_and_CISplatin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-02-01	Health Service Executive	Indication approved for reimbursement.